Mariner’s Larimar Therapeutics LRMR Stock Holding History

Mariner’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Buy	114,445 +82,800	+262%	+$329K	﹤0.01%	2726
2026 Q1	$142K	Buy	+31,645	New	+$126K	﹤0.01%	3254

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Mariner's LRMR Position: Q2 2026 in Review

Mariner increased its Larimar Therapeutics (LRMR) stake by 262% in Q2 2026, buying an estimated $329K and bringing the position to 114,445 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

Mariner first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Mariner held 114,445 shares of Larimar Therapeutics worth $349K as of Q2 2026.
Mariner bought 82,800 Larimar Therapeutics shares in Q2 2026, an estimated $329K.
Larimar Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2726 holding.
Mariner first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.